Bagsværd, Denmark, 18 March 2016 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted:
Financial year 2015 and 2016
- The Company's audited Annual Report 2015.
- The actual remuneration of the Board of Directors for 2015 and the remuneration level for 2016.
- Distribution of profit according to the adopted Annual Report 2015. The dividend will be DKK 6.40 per A and B share of DKK 0.20.
Elections
- Re-election of Göran Ando as chairman and Jeppe Christiansen as vice chairman of the Board of Directors.
- Re-election of Bruno Angelici, Sylvie Grégoire, Liz Hewitt and Mary Szela as members of the Board of Directors.
- Election of Brian Daniels as new member of the Board of Directors.
Re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as the Company's auditor.
- Reduction of the Company's B share capital by cancellation of part of the Company's own holding of B shares. The Company's B shares are reduced by DKK 10,000,000 from DKK 412,512,800 to DKK 402,512,800.
- Authorisation to the Board of Directors to increase the Company's share capital.
- Authorisation to the Board of Directors until the next Annual General Meeting to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital.
Other
- Amendments to the Articles of Association regarding
- abolishment of bearer shares
- the change of NASDAQ OMX Copenhagen A/S' name to Nasdaq Copenhagen A/S
- deletion of the requirement that all members of the Executive Management shall be registered with the Danish Business Authority
- company announcements may be prepared in English only, if decided by the Board of Directors
- Revised Remuneration Principles.
Composition of the Board of Directors and its committees
After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.
The Board of Directors, including its committees are now composed as follows:
- Göran Ando (chairman of the Board, of the Nomination Committee and of the Remuneration Committee)
- Jeppe Christiansen (vice chairman and member of the Remuneration Committee and the Audit Committee)
- Bruno Angelici (member of the Nomination Committee)
- Brian Daniels
- Sylvie Grégoire (member of the Audit Committee)
- Liz Hewitt (chairman of the Audit Committee and member of the Nomination Committee)
- Liselotte Hyveled (employee representative and member of the Nomination Committee)
- Anne Marie Kverneland (employee representative)
- Søren Thuesen Pedersen (employee representative and member of the Remuneration Committee)
- Stig Strøbæk (employee representative and member of the Audit Committee)
- Mary Szela (member of the Remuneration Committee)
Further information
Media: | ||
Katrine Sperling | +45 3079 6718 | krsp@novonordisk.com |
Ken Inchausti (US) | +1 267 809 7552 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
Kasper Veje | +45 3079 8519 | kpvj@novonordisk.com |
Company announcement No 23 / 2016
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire